• Loading stock data...
Est. 2004

LEVERAGE OUR MASSIVE INVESTOR AUDIENCE!

Stock Investors · Accredited Investors · Hedge Fund Investors

Learn More or Call (407) 374-6986

Monday 12/17/2018
SMALL CAP MARKET NEWS

We release small market news updates daily, 5 times a week! Always check back to get the inside scoop on what going on.


LEVERAGE OUR MASSIVE INVESTOR AUDIENCE!

Stock Investors · Accredited Investors · Hedge Fund Investors

Learn More

My Diagnostic

  • 11:24 AM

    Reinvigorating its Brand & Clarifying its Mission Statement PR Newswire SAN DIEGO, Oct. 11, 2017 SAN DIEGO, Oct. 11, 2017, MYDX, /PRNewswire/ — MyDx, Inc. (OTC: MYDX), a science and technology company and creator of MyDx® (My Diagnostic), the first multi-use handheld chemical analyzer designed for Cannabis professionals and retail consumers to correlate the chemical profile of cannabis with how it makes them feel and which ailments it alleviates, today announced the launch of its new website, www.mydxlife.com, a reimagining of its brand with greater

    Read more
  • 10:31 PM

    NVIV HRZL & VGGL More Info @ Web Site: www.OTCMarkets.com Wednesday, November 12th – Follow us on Twitter @PUBLIC_WIRE VGGL – UP 117% HWKR – UP 104% HRZL – UP 73% Note: Over $2.2 mil in dollar volume in trading today NVIV – UP 37% Note: Big trading day…over $6.5 mil in dollar volume and over 1,800 trades EGYH – UP 37% SUB PENNY GAINERS – PMCM +200%, DEWM +100%, and DROP +25% Stocks that took a tumble today- KIORQ

    Read more
  • 1:42 PM

      CAMBRIDGE, Mass., May 06, 2014 (BUSINESS WIRE) — InVivo Therapeutics Holdings Corp. (NVIV), a biomaterials company with innovative technologies for drug delivery with a focus on treatment of spinal cord injuries, today announced the pricing of an underwritten public offering of 12,175,000 shares of common stock and warrants to purchase up to an aggregate of 6,087,500 shares of common stock, at an offering price of $1.15 per share of common stock and $0.00001 per warrant. The warrants have a

    Read more
  • 9:43 PM

        Scaffold Designed to Facilitate Neural Growth in Spinal Cord Injury CAMBRIDGE, Mass., Apr 28, 2014 (BUSINESS WIRE) — InVivo Therapeutics Holdings Corp. (NVIV) announced today that it has begun shipment of its innovative investigational device, a degradable polymer Neuro-Spinal Scaffold for spinal cord injury (SCI) patients, for initiation of the company’s first clinical trial. InVivo has pioneered a new treatment platform utilizing a biocompatible polymer-based device that is intended to promote structural support for spinal cord regeneration while

    Read more
Public Wire Banner